💊Ono Enters into New Collaboration Agreement with Merus N.V.
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director and CEO,
Gyo Sagara; “ONO”) announced today that it entered into a collaboration agreement with
Merus N.V. (Utrecht, the Netherlands; Chief Executive Officer, Ton Logtenberg, Ph.D.;
“Merus”) focused on the development of human bispecific antibodies that bind to a combination
of targets designed for the treatment of autoimmune diseases.